Written by Ad OpsIntroduction to Avidekel: A Flagship High-CBD Cultivar
Avidekel is a renowned high-CBD, ultra-low-THC cannabis strain developed for medical users seeking therapeutic effects without significant intoxication. Commonly referred to as a CBD-rich, or chemotype III, cultivar, Avidekel typically expresses CBD concentrations in the mid-teens to high teens, with THC often below 1 percent by dry weight. This profile makes it a leading choice for patients sensitive to THC or for daytime use where clarity and functionality are essential.
The strain has earned an international reputation for consistency, especially in clinical and compassionate-use settings. It aligns closely with the needs of patients managing epilepsy, inflammation, anxiety, pain, and neurodegenerative symptoms, where CBD-dominant ratios are often preferred. As the target strain for this review, Avidekel stands out for its reproducible cannabinoid ratios, medical pedigree, and grower-friendly structure.
In legal markets, Avidekel appears in both dried flower and extract formats, including standardized oils and tinctures. While the exact percentages vary by batch and producer, licensed labs have repeatedly measured CBD:THC ratios exceeding 15:1, and often surpassing 25:1. This reliability has cemented Avidekel as a cornerstone cultivar in the global discussion of evidence-informed medical cannabis.
History and Development
Avidekel was originally bred in Israel in the early 2010s by the pioneering medical cannabis company Tikun Olam. The goal was explicit and ambitious: create a stable strain with high CBD and minimal THC to expand access for patients who could not tolerate psychoactive effects. By 2012–2013, early public reports and patient registries described Avidekel as containing negligible THC alongside robust CBD levels.
The strain emerged during a formative period for medical cannabis in Israel, where clinical collaborations and registries helped standardize plant profiles. Israel’s early medical cannabis program, one of the first structured frameworks outside North America and Europe, provided a unique environment for breeding to medical endpoints. Avidekel’s release coincided with the growing scientific interest in CBD’s anticonvulsant and anti-inflammatory properties.
In subsequent years, Avidekel became a reference cultivar in patient communities and among researchers looking to observe high-CBD outcomes in real-world settings. While it was not the only high-CBD strain in circulation, its brand-standard consistency and transparency set it apart. These attributes helped Avidekel gain international recognition and inspired similar breeding projects worldwide focused on high-CBD chemotypes.
Genetic Lineage and Breeding Notes
The exact genetic lineage of Avidekel has not been fully disclosed by its original breeders. What is known is that Avidekel represents a stabilized high-CBD, low-THC chemotype achieved through targeted selection and backcrossing. Breeders prioritized CBD synthase expression while suppressing THC synthase, resulting in CBD-dominant offspring with predictable chemotypic outcomes.
In practice, this type of breeding often involves crossing CBD-rich phenotypes identified in mixed or landrace populations, followed by marker-assisted selection. The aim is to retain agronomic traits like vigor, internode spacing, and disease resistance while locking in the CBD-forward cannabinoid pathway. Avidekel is often described as indica-leaning, suggesting contributions from broadleaf drug-type ancestors.
Growers report that Avidekel tends to produce uniform phenotypes, a hallmark of careful in-house line work. Phenotypic stability is important for medical providers because it supports batch-to-batch consistency in both raw flower and derivative products. While the parentage is proprietary, the resulting chemotype reflects elite selection for medical needs rather than recreational potency.
Appearance and Morphology
Avidekel plants generally display indica-dominant morphology: stocky stature, broad leaflets, and tight internodal spacing. Indoor-grown plants commonly finish between 90 and 120 cm tall with topping or training, while outdoor specimens can reach 150–200 cm in favorable climates. The canopy tends to be dense, with lateral branches that respond well to low-stress training and scrogging.
Flowers mature into compact, resin-rich buds with a dense calyx structure and relatively modest fox-tailing, if environmental conditions are stable. Trichomes are abundant despite the low THC, with milky heads containing CBDa predominating toward late flower. Mature buds typically show forest-green hues accented by orange to amber pistils and moderate sugar-leaf coverage that trims cleanly.
Under optimized nutrition and lighting, average indoor yields range from 400 to 550 grams per square meter using a multi-top canopy. Outdoor plants, given a long vegetative period and adequate sunlight, can produce 600 to 1,200 grams per plant. Expect an 8–9 week flowering period in most setups, with some phenotypes finishing closer to 56 days if pushed.
Aroma Profile
Avidekel’s aroma is generally described as herbal, earthy, and pine-forward, with secondary notes of pepper and faint citrus. The dominant aromatic impressions line up with a terpene backbone of myrcene, beta-caryophyllene, and alpha-pinene. In cured flower, the scent can be fresh and woody, reminiscent of a conifer grove with a peppery edge.
Total terpene content typically sits between 1.2 and 2.0 percent by weight, which is moderate by medical cultivar standards. Myrcene often leads at 0.3–0.6 percent, contributing to the earthy base and subtle sedative character. Alpha-pinene and beta-caryophyllene combine to give a bright, resinous lift and a warm spice finish.
When ground, the bouquet opens with more pronounced herbal and pine notes, sometimes evoking rosemary or juniper. Storage quality heavily influences terpene expression; airtight containers at 55–62 percent relative humidity preserve the top notes. Properly cured batches maintain aromatic integrity for several months when kept below 20°C and away from light.
Flavor Profile
On the palate, Avidekel mirrors its aromatic profile with earthy, piney, and lightly peppered flavors. The initial inhale is smooth and herbal, often with a hint of citrus zest or eucalyptus-like coolness from pinene. Exhales tend to carry a warm spice characteristic associated with beta-caryophyllene.
Vaporization at 175–185°C emphasizes the brighter, pine-led terpenes while keeping the herbal base intact. At higher temperatures, around 190–200°C, the flavor becomes heavier and more peppery, with increased extraction of caryophyllene and humulene. Combustion mutes some of the top notes but preserves the earthy backbone.
Extracts and tinctures derived from Avidekel often taste milder than the flower, especially if terpenes are partially removed during processing. Formulators who reintroduce botanical or cannabis-derived terpenes tend to match a pine-herb profile to maintain strain identity. Sublingual oils are commonly blended with neutral carrier oils like MCT to minimize bitterness and enhance consistency.
Cannabinoid Profile and Ratios
Avidekel is defined by its high-CBD, low-THC composition. In licensed markets, lab-tested dried flower commonly reports CBD between 12 and 20 percent by weight, with THC ranging from 0.3 to 1.2 percent. This translates to CBD:THC ratios most often between 15:1 and 30:1, and occasionally higher depending on harvest timing and phenotype.
In raw plant material, CBD is present primarily as CBDa, which decarboxylates to CBD when heated or during processing. Harvested flowers may show CBDa values in the 15–22 percent range with total THC (THCa + Δ9-THC) kept under 1–1.5 percent. After decarboxylation, final CBD values typically land around 13–18 percent due to mass loss from CO2 release.
Minor cannabinoids are present at trace to low levels, supporting the entourage matrix without overshadowing CBD. CBG frequently appears in the 0.1–1.0 percent range, and CBC often measures 0.1–0.5 percent. THCV and CBDV can be detected in trace amounts (often below 0.1 percent), varying by phenotype and environmental conditions.
Terpene Profile and Minor Compounds
Avidekel’s terpene profile is led by myrcene, beta-caryophyllene, and alpha-pinene, with humulene and linalool as common supporting players. Typical ranges for individual terpenes in well-grown flower are myrcene 0.3–0.6 percent, beta-caryophyllene 0.2–0.5 percent, alpha-pinene 0.15–0.4 percent, humulene 0.08–0.25 percent, and linalool 0.05–0.15 percent. Total terpene content generally measures between 1.2 and 2.0 percent by weight.
This combination yields an earthy-pine base with a peppery, slightly woody finish. Myrcene contributes to perceived relaxation and may synergize with CBD’s calming effects without adding intoxication. Beta-caryophyllene is a dietary cannabinoid that binds to CB2 receptors, potentially amplifying anti-inflammatory signaling alongside CBD.
Notably, alpha-pinene is associated with alertness and bronchodilation, which helps explain Avidekel’s clear-headed feel despite its relaxing undertone. Minor compounds such as guaiol, ocimene, and trace terpinolene may appear depending on phenotype and terroir, usually below 0.05 percent each. Extracts retain variable fractions of these terpenes depending on processing method, with cold ethanol and gentle CO2 often preserving more of the original bouquet than high-heat techniques.
Experiential Effects and User Reports
Avidekel’s effects are characteristically non-intoxicating and functional, with relaxation that does not impair cognition for most users. The most common reports include a calm body feel, reduced stress, and mild muscle ease within 15–30 minutes of inhalation or 45–90 minutes of oral ingestion. Because THC levels are typically below 1 percent, classic euphoria and time distortion are minimal or absent.
Many consumers describe Avidekel as a daytime-compatible strain that smooths anxious edges and supports focus. The alpha-pinene component often contributes to a fresh, alert mood, while myrcene and caryophyllene deepen the body calm. At higher doses, particularly via edibles or tinctures, some users experience gentle sedation suitable for evening wind-down.
Side effects are generally mild and align with typical cannabis experiences: dry mouth, dry eyes, and occasional lightheadedness in sensitive individuals. Surveys of high-CBD users commonly note dry mouth in approximately 15–30 percent of sessions and drowsiness in 10–20 percent at higher doses. As always, individual responses vary, and starting with a low dose is prudent for new users.
Potential Medical Applications and Evidence
Avidekel’s high-CBD, low-THC profile aligns with a broad range of potential medical uses. CBD has been studied for anticonvulsant properties, with clinical evidence supporting its use in certain epilepsy syndromes. While Avidekel specifically is a cultivar rather than an FDA-approved medication, its chemotype is consistent with formulations used in published studies.
Observational data from medical cannabis programs, particularly in Israel, have reported improvements in chronic pain, sleep quality, and anxiety with high-CBD preparations. For example, real-world cohorts using low-THC, CBD-forward oils have shown clinically meaningful reductions in pain scores, often by 20–30 percent on numeric rating scales over several months. Patient-reported outcomes also suggest improved daily function and decreased reliance on certain analgesics, though results vary and controlled trials remain essential.
In inflammatory conditions like arthritis or inflammatory bowel disease, the CB2-binding activity of beta-caryophyllene and CBD’s immunomodulatory effects may play complementary roles. Small studies and case series have found that CBD-rich regimens improved patient-reported quality of life and reduced symptom severity, without significant psychoactive side effects. Anxiety and sleep disturbances also commonly respond to CBD-dominant products, with many patients reporting decreased anxiety intensity and latency to sleep onset.
Pediatric and neurological contexts require careful medical supervision, but high-CBD, low-THC oils have been examined for autism spectrum-related symptoms, spasticity, and seizure frequency. In several observational studies, a majority of participants experienced some improvement in either core symptoms, comorbid anxiety, or sleep, though not all responders maintained benefit long-term. Importantly, because Avidekel’s THC level is very low, it may be suitable for individuals who cannot tolerate THC side effects, but medical guidance and product testing are paramount.
Avidekel’s non-intoxicating nature also makes it a candidate for daytime pain modulation in conditions like neuropathy, fibromyalgia, and post-surgical recovery phases. CBD’s interaction with TRPV1 and 5-HT receptors may contribute to analgesic and anxiolytic effects reported by users. Nonetheless, dosing should be individualized, titrated slowly, and coordinated with a clinician, especially for those on polypharmacy regimens due to potential CYP450 interactions.
Comprehensive Cultivation Guide: Overview and Goals
Cultivating Avidekel successfully means targeting two outcomes: healthy yields and preservation of its high-CBD, low-THC chemotype. The strain is moderately vigorous and forgiving, but like many CBD-dominant plants, it rewards precise environmental control. Growers should emphasize even canopy development, steady nutrition, and careful harvest timing to capture peak CBD.
Avidekel thrives indoors or outdoors with appropriate climate management. Indoors, expect 56–63 days of flowering; outdoors, plan for mid- to late-October harvest in temperate zones. Photoperiod plants respond predictably to training and typically do not stretch excessively, making Avidekel suitable for tents and smaller rooms.
Plan your grow with repeatable metrics: light intensity, VPD, irrigation, and substrate pH. Stable parameters improve cannabinoid expression and reduce hermaphroditic stress. Because medical users prioritize consistency, standardizing your process is as important as selecting strong genetics.
Cultivation Environment: Light, Temperature, and Humidity
During vegetative growth, target 22–26°C daytime temperatures and 60–65 percent relative humidity, with a VPD around 0.8–1.0 kPa. In flowering, shift to 24–26°C days and 45–50 percent RH early bloom, tapering to 40–45 percent late bloom to curb botrytis risk. Nighttime temperatures 2–3°C lower than daytime help maintain internode tightness without shocking the plant.
Avidekel performs well under LED or HID lighting. Flowering PPFD of 700–900 µmol/m²/s at canopy translates to a DLI of roughly 35–45 mol/m²/day on a 12/12 schedule. If supplementing CO2 to 800–1,200 ppm, plants can comfortably utilize the upper PPFD range, provided nutrients and irrigation are adjusted accordingly.
Maintain strong air exchange with 20–30 air changes per hour in sealed or semi-sealed rooms, and ensure oscillating fans gently move leaves without causing windburn. Keep leaf surface temperatures monitored with an infrared thermometer; LEDs often warrant slightly warmer air temps due to lower radiant heat. Avoid RH spikes above 60 percent in late bloom, as dense Avidekel colas can be susceptible to mold if airflow is inadequate.
Cultivation Media and Nutrition
Avidekel grows well in living soil, coco coir, or hydroponic systems. In soil, aim for a pH of 6.3–6.8; in coco and hydro, maintain 5.8–6.2. Electrical conductivity during mid-veg is typically 1.2–1.6 mS/cm, rising to 1.6–2.0 mS/cm in mid-flower for vigorous phenotypes.
CBD-forward cultivars often benefit from a balanced NPK profile with a slight lean toward potassium and sulfur during bloom to support resin development. Calcium and magnesium should be kept steady, especi
